Tevogen Bio Regains Nasdaq Compliance Following Reverse Stock Split

summarizeSummary

Tevogen Bio Holdings Inc. announced it has formally regained compliance with Nasdaq's minimum bid price requirement, a direct result of its recent 1-for-50 reverse stock split.

check_boxKey Events

• Regained Nasdaq Compliance

  On March 20, 2026, Tevogen Bio Holdings Inc. received written notice from The Nasdaq Stock Market LLC confirming it had regained compliance with Listing Rule 5450(a)(1) regarding the minimum bid price requirement.

• Matter Closed

  The Notification Letter indicates that the compliance matter is now closed, removing the immediate risk of delisting.

• Result of Reverse Stock Split

  This compliance was achieved following the implementation of a 1-for-50 reverse stock split, which became effective on March 6, 2026, as previously disclosed in a Form 8-K on March 4, 2026.

auto_awesomeAnalysis

This 8-K filing formally confirms Tevogen Bio Holdings Inc. has regained compliance with Nasdaq's minimum bid price requirement, removing an immediate delisting threat. This positive development follows a 1-for-50 reverse stock split, which was implemented to boost the share price above the $1.00 threshold. While reverse splits are often viewed negatively as a sign of distress, successfully regaining compliance provides stability and ensures the company's continued listing on The Nasdaq Global Market. This filing formalizes the news that was already reported by GlobeNewswire on March 25, 2026.